ReviewImmune network2026
Respiratory Microbiome Remodeling in Aging: Implications for Immunosenescence and Therapeutic Intervention.
Review in Immune network, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Aging involves progressive declines in lung structure and immune function, increasing the incidence and severity of respiratory diseases and reducing vaccine responsiveness. Meanwhile, the respiratory tract harbors a dynamic microbial ecosystem that contributes to immune homeostasis and colonization resistance. Growing evidence indicates that aging disrupts this host-microbe balance within the respiratory tract; however, the mechanisms and therapeutic implications remain incompletely integrated. This review summarizes age-related remodeling of the respiratory microbiome. Beyond compositional shifts, aging alters microbial functions, including metabolic output and resilience to perturbation, exhibiting downstream effects on epithelial barriers, mucus clearance, and immune priming. Furthermore, as the microbiome-immune axis is modifiable, microbiome-targeted therapies represent key opportunities to restore respiratory homeostasis during aging. These interventions, combined with senescence- and cytokine-directed immunomodulation and vaccine optimization using adjuvants and mucosal immune-informed designs, may reduce infection burden and chronic lung disease progression in older populations. Together, this review highlights that a deeper understanding of age-related respiratory microbiome remodeling and its interplay with immunosenescence will be essential for the rational design of microbiome-informed therapies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.